StockData
Shuttle Pharmaceuticals Holdings, Inc. logo

Shuttle Pharmaceuticals Holdings, Inc. (SHPH) stock

SHPHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Sep 24, 2026Score 5/30
$4.24−0.29 (-6.40%)

Close on Nov 16, 2026Market cap $4.24MP/E –Yield –

Shuttle Pharmaceuticals r&d expenses

Research and development expenses are spending on new products and technology.

Shuttle Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $1.78M, down 64.3% year over year. For fiscal 2025 it was $4.05M, up 12.0% from the year before. The highest annual figure on record is $4.05M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$4.05M+12.0%
FY2024Dec 31, 2024$3.62M+2.9%
FY2023Dec 31, 2023$3.52M+235.8%
FY2022Dec 31, 2022$1.05M+2.5%
FY2021Dec 31, 2021$1.02M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$55.66K-94.6%
Q1 FY2026Mar 31, 2026$267.24K-83.0%
Q4 FY2025Dec 31, 2025$511.88K-48.1%
Q3 FY2025Sep 30, 2025$943.48K-32.6%
Q2 FY2025Jun 30, 2025$1.03M+58.8%
Q1 FY2025Mar 31, 2025$1.57M+168.5%
Q4 FY2024Dec 31, 2024$986.41K+38.8%
Q3 FY2024Sep 30, 2024$1.40M+34.0%
Q2 FY2024Jun 30, 2024$645.72K-23.1%
Q1 FY2024Mar 31, 2024$586.10K-36.4%
Q4 FY2023Dec 31, 2023$710.45K+611.2%
Q3 FY2023Sep 30, 2023$1.05M+56.2%
Q2 FY2023Jun 30, 2023$839.67K+901.2%
Q1 FY2023Mar 31, 2023$921.80K+211.5%
Q4 FY2022Dec 31, 2022$99.89K-77.4%
Q3 FY2022Sep 30, 2022$669.04K+257.9%
Q2 FY2022Jun 30, 2022$83.87K–
Q1 FY2022Mar 31, 2022$295.92K–
Q4 FY2021Dec 31, 2021$442.12K–
Q3 FY2021Sep 30, 2021$186.96K–

More Shuttle Pharmaceuticals figures

See a number that looks wrong?